Lund Sept 15, 2011
During the next major European nuclear medicine congress in Birmingham, EANM ‘11 (European Association of Nuclear Medicine) which takes place October 15 to 19, EXINIs systems will be represented at a number of presentations during the congress scientific program. EXINI will also participate as exhibitors at the Congress.
The 24th annual congress of European nuclear medicine in Birmingham is a follow up from last year congress in Vienna. During the congress several scientific studies will be presented, both on studies made by products of EXINI and other were the company's software has been used for the analysis of study results. The conclusions of the studies presented the positive characteristics of the systems for doctors as well as for patients.
Selections from Congress scientific program:
-
"Progression of Disease in Bone in Patients with Prostate Cancer - an Automated Serial Analysis of Whole Body Bone Scans" Reza Kaboteh et al. Sahlgrenska University Hospital, Gothenburg, Sweden A study to evaluate EXINI bone™ as a method to assess progression / regression of metastatic prostate cancer.
Conclusion: "A completely automated method for detection of new lesions in serial bone scans can be used for the analysis of progression in serial bone scans from prostate cancer patients. Application of the method as a clinical decision support tool or in clinical trials appears to have significant potential."
-
"Prediction of survival in prostate cancer patients by bone scan index using computer assisted diagnosis system" Dr.Mana Yoshimura et al. Tokyo Medical University, Japan A study that compares a manual and time-consuming method to calculate the Bone Scan Index * (BSI) with an automated method implemented with EXINI Bone ™.
Conclusion: "This quantification method of BSI will be able to predict the survival of prostate cancer automatically instead of EOD score."
- "Computer Aided Diagnosis systems for the Interpretation of Myocardial Perfusion Scintigrams" Lena Johansson et al. Sahlgrenska University Hospital, Gothenburg, Sweden A comparative study of EXINI Heart ™ and another decision support software to assessment of myokardskintigrafi. Conclusion: "EXINI heart™ shows a significantly higher specificity for ischemia than PERFEX™. This difference in performance should be taken in consideration when software packages are used in the clinical routine. These results show the high potential for neural networks as computer aided diagnosis system."
EXINI continues their intensive development and launch of products within medical decision support. The goal is to offer software for analysis that improves, simplifies and make the daily work of doctors more efficient in the interpretation of radiology images. That EXINI is so well represented in the scientific program at EANM, shows that interest in the company’s products is high.
* Bone Scan Index has in several studies proved to be a very good imaging marker for prediction of prostate and breast cancer patients with bone metastases. Studies has for instance been made at the Memorial Sloan-Kettering Cancer Center in New York.
For more information, please contact:
Magnus Aurell, CEO, Phone: +46 46-286 54 25, E-mail: magnus.aurell@exini.com
About EXINI Diagnostics AB (publ)
EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make their own interpretation of radiology images and providing diagnostic suggestions. In this way the system is used as a decision support for diagnosing sparkling doctor. EXINI is working on products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. Founded in 1999 by Professor Lars Edenbrandt and currently has 13 employees. EXINI is listed on the stock market square and has about 400 shareholders. Principal owner, Bo Håkansson.
EXINI Diagnostics AB (Publ), Ideon Science Park, Scheelevägen 19A, SE-223 70 Lund, Sweden Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com, VAT-no: SE556576199501